Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00006490 · ClinicalTrials.gov registry record

A Comparison of Two Tests for Anti-HIV Drug Resistance

A clinical trial of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Completed
Registry status
600
Enrollment target
20
Study locations

NCT00006490: Completed study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

NCT00006490 is a study of HIV Infections that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 600 participants, above the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (35% higher). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00006490, a study of HIV Infections, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

COMPLETED
Registry status
600 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to compare 2 different types of tests of the HIV virus to see which specific anti-HIV drugs would work the best. Drug resistance is a major reason for therapy failure in HIV patients. Two types of tests can detect resistance to drugs: 1) genotyping (sequencing), which looks at the DNA sequence of a virus to see whether it has developed any genetic resistance; 2) phenotyping, which looks at the ability of different drugs to suppress virus growth in the laboratory. Genotyping and phenotyping can help doctors give patients the most effective drug therapy.

Conditions Studied

Study Locations (20)

California

  • Univ of Southern California / LA County USC Med Ctr - Los Angeles
  • UCLA CARE Ctr - Los Angeles
  • Willow Clinic - Menlo Park
  • University of California San Francisco - San Francisco
  • Univ of California San Francisco - San Francisco
  • Santa Clara Valley Med Ctr / AIDS Community Rsch Consortium - San Jose
  • San Mateo AIDS Program / Stanford Univ - Stanford
  • Stanford Univ Med Ctr - Stanford
  • Harbor UCLA Med Ctr - Torrance

Illinois

  • Northwestern Univ Med School - Chicago
  • Rush Presbyterian - Saint Luke's Med Ctr - Chicago
  • The CORE Ctr - Chicago

Colorado

  • Denver Dept of Health and Hosps - Denver
  • Univ of Colorado Health Sciences Ctr - Denver

Alabama

  • Univ of Alabama at Birmingham - Birmingham

Florida

  • Univ of Miami School of Medicine - Miami

Georgia

  • Emory Univ - Atlanta

Hawaii

  • Univ of Hawaii - Honolulu

Maryland

  • Johns Hopkins Hosp - Baltimore

Trial Details

FieldValue
Enrollment Target 600 participants

What the finished NCT00006490 record still lists

NCT00006490 is an observational study that tracks outcomes without assigning an intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap, above the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (35% higher).

The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 0 interventions.

NCT00006490 names 20 study sites across 9 states, led by California, Illinois, Colorado.

Frequently Asked Questions

What is clinical trial NCT00006490 about?

NCT00006490 is a clinical study titled "A Comparison of Two Tests for Anti-HIV Drug Resistance". The purpose of this study is to compare 2 different types of tests of the HIV virus to see which specific anti-HIV drugs would work the best. Drug resistance is a major reason for therapy failure in HIV patients. Two types of tests can detect resistance to drugs: 1) genotyping (sequencing), which l...

What is the current status of trial NCT00006490?

This trial is currently completed. The enrollment target is 600 participants.

What conditions does trial NCT00006490 study?

This clinical trial studies the following conditions: HIV Infections.

Who is sponsoring clinical trial NCT00006490?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00006490 being conducted?

This trial has 20 study locations across Alabama, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00006490's enrollment target sits among peer trials

600 51st of 542 higher than 490 of 542 other HIV Infections trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00004317 · 600 participants · Phase 4

    Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis

  • NCT00209235 · 600 participants · NA

    Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments

  • NCT01473784 · 600 participants · NA

    Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck

  • NCT01866371 · 600 participants

    High Resolution Retinal Imaging

Source: ClinicalTrials.gov NCT00006490, the US trial registry maintained by the National Library of Medicine. NCT00006490 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.